Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | RAB9A | P51151 | 10/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128727 | 0.85 | ALDH1A1 (0.57) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL2791167 | 0.84 | ALDH1A1 (0.56) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL3066648 | 0.84 | ALDH1A1 (0.60) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL17761982 | 0.81 | ALDH1A1 (0.50) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL1225966 | 0.81 | ALDH1A1 (0.59) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL21938816 | 0.81 | RAB9A (0.66) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23189127 | 0.80 | ALDH1A1 (0.52) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL2328124 | 0.79 | NOTUM (0.43) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL14453815 | 0.77 | VHL (0.45) | MAPTALDH1A1RAB9ANPC1S1PR1 | |
| SCHEMBL18819583 | 0.77 | SMN1; SMN2 (0.40) | MAPTALDH1A1RAB9ANPC1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137639-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | CYP3A7, CYP2C19, CYP3A5 | MAPT 1336/4885ALDH1A1 560/4885RAB9A 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.